Breast Cancer
News
ALTTO: Dual HER2 blockade offers no survival edge in adjuvant breast cancer treatment
Major finding: Disease-free survival at 4 years was 86% with trastuzumab, 88% with concurrent lapatinib plus trastuzumab, and 87% with trastuzumab...
News
Cochrane review: Trastuzumab benefit outweighs harm for advanced HER2-positive breast cancer
Key clinical point: Trastuzumab reduces breast cancer mortality by one-fifth, but the risk of heart toxicity is between three and four times more...
News
VIDEO: ASCO 2014 roundtable on breast cancer research
Conference Coverage
VIDEO: New option arises for young women with hormone-sensitive breast cancer
Conference Coverage
Goserelin improves fertility in HR-negative breast cancer
Key clinical point: Goserelin may be offered to young patients with hormone receptor–negative breast cancer who desire to preserve fertility or...
Conference Coverage
VIDEO: Less frequent zoledronic acid is safe, retains efficacy
Conference Coverage
VIDEO: Goserelin helps dodge ovarian failure in HR-negative breast cancer
News
ASCO: Extend adjuvant endocrine therapy to 10 years
Major Finding: Emerging research from international randomized trials has demonstrated that women who continue adjuvant endocrine therapy for an...
News
ASCO 2014: Dr. Hope S. Rugo gives her top picks in breast cancer research
From the Editor
Taking the data and findings into the real-world setting
News
Breast cancer fear contributes to prophylactic mastectomy rate
Key clinical point: Fear of breast cancer recurrence results in many unnecessary contralateral prophylactic mastectomies.Major finding: Women with...